Lobe Sciences (DE:LOBE)
FRANKFURT:LOBE
LOBE Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EST
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€15.85M
Enterprise Value€19.53M
Total Cash (Recent Filing)€4.96M
Total Debt (Recent Filing)€316.49K
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding284,102,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest reported debt reduces near-term balance-sheet pressure and interest burden, giving management more flexibility to prioritize R&D and clinical programs without immediate refinancing. This structural cushion supports operations over the next several quarters.
Gross Profit When Revenue ExistedHistoric episodes of meaningful gross profit indicate the company’s underlying cost structure can support positive unit economics when sales resume. If clinical programs translate into commercial revenue, margin expansion is a realistic structural path rather than starting from fundamentally unprofitable operations.
Focused On Psychedelic TherapeuticsA clear strategic focus on psychedelic-derived therapies targets structural demand in mental health and neurology. Specialized R&D positioning and domain focus can create durable competitive advantages if clinical progress and regulatory acceptance continue over the medium term.
Bears Say
No Revenue; Sizable LossesPersistent zero revenue and large operating losses mean the business is not self-sustaining. This structurally increases reliance on external financing to fund trials and operations, raises execution risk for development programs, and constrains long-term strategic optionality.
Negative Operating & Free Cash FlowConsistent negative operating and free cash flow indicate ongoing cash burn and limited internal funding capacity for clinical milestones. Over months, this creates durable financing pressure, potential dilution, and the risk of interrupted development timelines absent reliable capital access.
Unstable Equity BaseHistoric periods of negative equity reflect an unstable capital base that can deter lenders, increase cost of capital, and limit strategic options. Structurally, this reduces financing flexibility and raises the likelihood of dilutive raises or restrictive financing terms.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was €0.01 and its highest was €0.08 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is €15.85M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 62 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in DE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---